Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement

summarizeSummary

Regeneron announced strong Q1 2026 financial results, a new $3.0 billion share repurchase program, a strategic drug pricing agreement with the U.S. government, and key regulatory approvals.

check_boxKey Events

• Strong First Quarter Financial Performance

  Total revenues increased 19% to $3.6 billion, and non-GAAP diluted EPS rose 15% to $9.47, driven by strong Dupixent and EYLEA HD sales. GAAP net income and EPS saw a slight decrease.

• New $3.0 Billion Share Repurchase Program Authorized

  The board of directors authorized a new program to repurchase up to an additional $3.0 billion of common stock, following $803 million in repurchases during Q1 2026.

• Strategic U.S. Government Pricing Agreement

  Regeneron entered into agreements with the U.S. government for Most-Favored-Nation Pricing on certain products, in exchange for not being subject to future government pricing mandates and receiving tariff relief for three years.

• Key Regulatory Approvals and Pipeline Progress

  The FDA approved EYLEA HD for extended dosing intervals up to 5 months, Dupixent for CSU in young children and AFRS, and Otarmeni (gene therapy) for genetic hearing loss. An NDA for cemdisiran was submitted, and a BLA for garetosmab received priority review.

auto_awesomeAnalysis

Regeneron Pharmaceuticals reported robust first-quarter 2026 financial results, with total revenues increasing 19% and non-GAAP diluted EPS rising 15%. The company also announced a significant new $3.0 billion share repurchase program, signaling strong confidence in its financial position and commitment to returning capital to shareholders. A strategic agreement with the U.S. government on drug pricing, including Most-Favored-Nation pricing for certain products, provides clarity and avoids future pricing mandates, while extending EYLEA's market exclusivity through a biosimilar settlement further strengthens its commercial outlook. These positive developments, alongside key regulatory approvals for EYLEA HD and the gene therapy Otarmeni, outweigh the temporary manufacturing interruption and mixed GAAP earnings.